Email Updates

Search form

You are here

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

Include in
Published Research

This phase I dose-escalating trial showed that iHIVARNA administration was safe and well tolerated, induced moderate HIV-specific T-cell responses and transiently increased different viral replication readouts. These data support further exploration of iHIVARNA in a phase II study.

November 13, 2018
AIDS